• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

用四种源自癌胚抗原的肽对胆道癌患者进行疫苗接种。

Vaccination of biliary tract cancer patients with four peptides derived from cancer-testis antigens.

作者信息

Aruga Atsushi

机构信息

Institute of Advanced Biomedical Engineering and Science; Tokyo Women's Medical University; Tokyo, Japan.

出版信息

Oncoimmunology. 2013 Jul 1;2(7):e24882. doi: 10.4161/onci.24882. Epub 2013 May 7.

DOI:10.4161/onci.24882
PMID:24073370
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3782136/
Abstract

In the context of a Phase I clinical trial, the long-term vaccination of advanced biliary tract cancer patients with peptides derived from four distinct cancer-testis antigens resulted in remarkable disease stability and in the elicitation of antigen-specific T-cell responses.

摘要

在一项I期临床试验中，用源自四种不同癌胚抗原的肽对晚期胆管癌患者进行长期疫苗接种，结果显示疾病显著稳定，并引发了抗原特异性T细胞反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74fe/3782136/763ddaa8ee6c/onci-2-e24882-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74fe/3782136/763ddaa8ee6c/onci-2-e24882-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74fe/3782136/763ddaa8ee6c/onci-2-e24882-g1.jpg

相似文献

1
Vaccination of biliary tract cancer patients with four peptides derived from cancer-testis antigens.用四种源自癌胚抗原的肽对胆道癌患者进行疫苗接种。
Oncoimmunology. 2013 Jul 1;2(7):e24882. doi: 10.4161/onci.24882. Epub 2013 May 7.
2
Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer.长期接种源自癌症睾丸抗原的多种肽可维持特异性 T 细胞应答，并实现晚期胆道癌的疾病稳定。
Clin Cancer Res. 2013 Apr 15;19(8):2224-31. doi: 10.1158/1078-0432.CCR-12-3592. Epub 2013 Mar 11.
3
Immunological responses to a multi-peptide vaccine targeting cancer-testis antigens and VEGFRs in advanced pancreatic cancer patients.针对晚期胰腺癌患者的癌症睾丸抗原和 VEGFRs 的多肽疫苗的免疫反应。
Oncoimmunology. 2013 Nov 1;2(11):e27010. doi: 10.4161/onci.27010. Epub 2013 Nov 5.
4
A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer.一项关于个性化肽疫苗联合低剂量环磷酰胺治疗胆管癌的随机II期试验。
Cancer Sci. 2017 May;108(5):838-845. doi: 10.1111/cas.13193. Epub 2017 May 5.
5
Therapeutic vaccination for cancer immunotherapy: antigen selection and clinical responses.用于癌症免疫治疗的治疗性疫苗接种：抗原选择与临床反应。
Hum Vaccin. 2011 Jan-Feb;7 Suppl:115-9. doi: 10.4161/hv.7.0.14573. Epub 2011 Jan 1.
6
Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis.晚期胆管癌的个性化肽疫苗接种：IL-6、营养状况和预先存在的抗原特异性免疫作为患者预后的可能生物标志物
Exp Ther Med. 2012 Mar;3(3):463-469. doi: 10.3892/etm.2011.424. Epub 2011 Dec 20.
7
Coordinated responses to individual tumor antigens by IgG antibody and CD8+ T cells following cancer vaccination.癌症疫苗接种后 IgG 抗体和 CD8+T 细胞对个体肿瘤抗原的协调反应。
J Immunother Cancer. 2018 Apr 5;6(1):27. doi: 10.1186/s40425-018-0331-0.
8
Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS.Ⅱ期临床试验显示，针对晚期头颈部癌症患者的多种肽疫苗接种可诱导免疫应答并改善总生存期。
Clin Cancer Res. 2015 Jan 15;21(2):312-21. doi: 10.1158/1078-0432.CCR-14-0202. Epub 2014 Nov 12.
9
WT1 peptide vaccine as a paradigm for "cancer antigen-derived peptide"-based immunotherapy for malignancies: successful induction of anti-cancer effect by vaccination with a single kind of WT1 peptide.WT1肽疫苗作为恶性肿瘤“癌症抗原衍生肽”免疫疗法的范例：通过接种单一WT1肽成功诱导抗癌效果。
Anticancer Agents Med Chem. 2009 Sep;9(7):787-97. doi: 10.2174/187152009789056958. Epub 2009 Sep 1.
10
Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens.多中心、Ⅱ期临床研究：用三种新型肿瘤睾丸抗原衍生肽进行晚期食管癌的癌症疫苗接种。
J Transl Med. 2012 Jul 9;10:141. doi: 10.1186/1479-5876-10-141.

引用本文的文献

1
Recent Advances in Cancer Vaccines: Challenges, Achievements, and Futuristic Prospects.癌症疫苗的最新进展：挑战、成就与未来前景
Vaccines (Basel). 2022 Nov 25;10(12):2011. doi: 10.3390/vaccines10122011.
2
Trial watch: Naked and vectored DNA-based anticancer vaccines.试验观察：裸 DNA 与载体 DNA 抗癌疫苗。
Oncoimmunology. 2015 Apr 2;4(5):e1026531. doi: 10.1080/2162402X.2015.1026531. eCollection 2015 May.
3
Classification of current anticancer immunotherapies.当前抗癌免疫疗法的分类。

本文引用的文献

1
Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer.长期接种源自癌症睾丸抗原的多种肽可维持特异性 T 细胞应答，并实现晚期胆道癌的疾病稳定。
Clin Cancer Res. 2013 Apr 15;19(8):2224-31. doi: 10.1158/1078-0432.CCR-12-3592. Epub 2013 Mar 11.
2
Clinical evaluation of therapeutic cancer vaccines.癌症治疗性疫苗的临床评估。
Hum Vaccin Immunother. 2013 May;9(5):1049-57. doi: 10.4161/hv.23917. Epub 2013 Mar 1.
3
Phase I clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer.
Oncotarget. 2014 Dec 30;5(24):12472-508. doi: 10.18632/oncotarget.2998.
4
Combined detection tumor markers for diagnosis and prognosis of gallbladder cancer.联合检测肿瘤标志物用于胆囊癌的诊断和预后评估。
World J Gastroenterol. 2014 Apr 14;20(14):4085-92. doi: 10.3748/wjg.v20.i14.4085.
肽疫苗联合替加氟-尿嘧啶+亚叶酸治疗晚期或复发性结直肠癌的Ⅰ期临床试验。
Oncol Rep. 2013 Mar;29(3):951-9. doi: 10.3892/or.2013.2231. Epub 2013 Jan 10.
4
Phase I clinical trial of a novel peptide vaccine in combination with UFT/LV for metastatic colorectal cancer.一种新型肽疫苗联合优福定/亚叶酸钙治疗转移性结直肠癌的I期临床试验。
Exp Ther Med. 2011 Jan;2(1):73-79. doi: 10.3892/etm.2010.182. Epub 2010 Dec 2.
5
Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens.多中心、Ⅱ期临床研究：用三种新型肿瘤睾丸抗原衍生肽进行晚期食管癌的癌症疫苗接种。
J Transl Med. 2012 Jul 9;10:141. doi: 10.1186/1479-5876-10-141.
6
Cancer peptide vaccine therapy developed from oncoantigens identified through genome-wide expression profile analysis for bladder cancer.基于膀胱癌全基因组表达谱分析鉴定的肿瘤相关抗原研制的癌症肽疫苗治疗。
Jpn J Clin Oncol. 2012 Jul;42(7):591-600. doi: 10.1093/jjco/hys069. Epub 2012 May 25.
7
Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival.肝细胞癌的聚糖蛋白 3 衍生肽疫苗的 I 期临床试验：免疫证据和提高总生存期的潜力。
Clin Cancer Res. 2012 Jul 1;18(13):3686-96. doi: 10.1158/1078-0432.CCR-11-3044. Epub 2012 May 10.
8
The immune score as a new possible approach for the classification of cancer.免疫评分作为癌症分类的一种新方法。
J Transl Med. 2012 Jan 3;10:1. doi: 10.1186/1479-5876-10-1.
9
Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma.术后树突状细胞疫苗联合活化 T 细胞转移在肝内胆管细胞癌患者中的临床应用。
J Hepatobiliary Pancreat Sci. 2012 Mar;19(2):171-8. doi: 10.1007/s00534-011-0437-y.
10
Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan.吉西他滨单药或联合顺铂治疗胆道癌患者：日本多中心比较研究。
Br J Cancer. 2010 Aug 10;103(4):469-74. doi: 10.1038/sj.bjc.6605779. Epub 2010 Jul 13.